Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
03:41pm, Thursday, 14'th Jul 2022 Zacks Investment Research
Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
10:15pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $40.92 in the latest trading session, marking a -1.25% move from the prior day.
How Its New Vaccine Could Propel GSK's Growth
11:00am, Monday, 11'th Jul 2022 The Motley Fool
GSK leads the race to deliver a vaccine for an untreated infectious disease.
How to Earn $10,000 a Year in Passive Retirement Income
03:00pm, Sunday, 10'th Jul 2022 The Motley Fool
You'll either need a decent chunk of change or some patience.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
10:00pm, Thursday, 07'th Jul 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.32, marking a +0.49% move from the previous day.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
10:15pm, Tuesday, 05'th Jul 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.30, marking a -1.03% move from the previous day.
2 First-Rate ETFs for Stock Dividends
10:55am, Sunday, 03'rd Jul 2022 The Motley Fool
These two ETFs produce both market-beating returns and high-yielding dividends.
GlaxoSmithKline (GSK) Stock Moves -0.8%: What You Should Know
10:00pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
12:49pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
05:21pm, Monday, 27'th Jun 2022 Zacks Investment Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
How Pfizer Plans to Unlock Another Mass-Market Vaccine
02:53pm, Monday, 27'th Jun 2022 The Motley Fool
The company turns its attention to another infectious disease that lacks a vaccine.
Why Sanofi May Be a Frontrunner in Endemic COVID-19
12:09pm, Saturday, 25'th Jun 2022 The Motley Fool
There is a promising outlook for its next generation of vaccines.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
04:30pm, Friday, 24'th Jun 2022 Zacks Investment Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
10:00pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed at $41.97 in the latest trading session, marking a +0.48% move from the prior day.
Top Analyst Reports for Alphabet, Bank of America & Charles Schwab
06:56pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Bank of America Corporation (BAC), and The Charles Schwab Corporation (SCHW).
